Back to top
more

Humacyte, Inc. (HUMA)

(Delayed Data from NSDQ)

$2.28 USD

2.28
5,793,581

-0.12 (-5.00%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $2.27 -0.01 (-0.44%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $4.37, signifying a +1.63% move from its prior day's close.

Zacks Equity Research

Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed at $5.05 in the latest trading session, marking a -1.94% move from the prior day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

by Zacks Equity Research

In the most recent trading session, Humacyte, Inc. (HUMA) closed at $5.82, indicating a +1.75% shift from the previous trading day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed at $5.70 in the latest trading session, marking a +0.53% move from the prior day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed at $5.46 in the latest trading session, marking a +0.09% move from the prior day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

Humacyte's (HUMA) ATEV BLA Review Period Extended by FDA

by Zacks Equity Research

Humacyte's (HUMA) Biologic License Application for its ATEV faces a delay as the FDA extends its review timeline, recognizing the product's potential impact on vascular trauma treatment.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Humacyte, Inc. (HUMA) stood at $7.85, denoting a -1.13% change from the preceding trading day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed the most recent trading day at $8.29, moving -0.72% from the previous trading session.

Zacks Equity Research

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

Humacyte, Inc. (HUMA) reachead $5.17 at the closing of the latest trading day, reflecting a -1.34% change compared to its last close.

Zacks Equity Research

Should You Buy Humacyte (HUMA) Ahead of Earnings?

by Zacks Equity Research

Humacyte (HUMA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma

by Zacks Equity Research

Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.

Zacks Equity Research

Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 0% and 68.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 0% and 14.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aeglea (AGLE) delivered earnings and revenue surprises of -5.26% and 16.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Voyager Therapeutics (VYGR) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 1,860% and 51.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?

by Zacks Equity Research

Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Humacyte (HUMA) Completes Enrollment in HAV Technology Study

by Zacks Equity Research

Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.

Zacks Equity Research

Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 12.50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zymeworks Inc. (ZYME) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 0.65% and 8.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -19.05% and 88.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?